within Pharmacolibrary.Drugs.ATC.L;

model L01XK04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.55,
    Cl             = 0.11166666666666666,
    adminDuration  = 600,
    adminMass      = 0.001,
    adminCount     = 1,
    Vd             = 0.42,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0033333333333333335,
    Tlag           = 15.0
  );

  annotation(Documentation(
    info ="<html><body><p>Talazoparib is an orally administered poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. It is currently approved for medical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with cancer following oral administration.</p><h4>References</h4><ol><li>Maaike A C Bruin, Gabe S Sonke, Jos H Beijnen, Alwin D R Huitema,Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology.,Clinical pharmacokinetics,2022<a href='https://pubmed.ncbi.nlm.nih.gov/36219340/'>https://pubmed.ncbi.nlm.nih.gov/36219340/</a></li><li>Yi Zeng, Oluwatobi Arisa, Cody J Peer, Antonio Fojo, William D Figg,PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics.,Seminars in oncology,2024<a href='https://pubmed.ncbi.nlm.nih.gov/37880048/'>https://pubmed.ncbi.nlm.nih.gov/37880048/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01XK04;
